Physician profile

Narayan P Verma

Neurology (Psychiatry & Neurology) · Warren, MI

NPI 1083680235

$21,479.55

in general payments reported to CMS, 2019-2025

45 companies · $848 in 2025

The $848 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,359.96
Education$543.17

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $6,929.24 2021-2025 Vraylar, Ubrelvy, Botox
Allergan, INC. $5,696.43 2019-2022
Livanova USA, INC. $1,668.74 2021-2025 Vns Therapy Sentiva Model 1000 Generator
Novartis Pharmaceuticals Corporation $1,557.09 2019-2025
Teva Pharmaceuticals USA, INC. $755.79 2019-2025 Austedo Xr, Ajovy, Austedo Xr
Biogen, INC. $748.66 2019-2023 Tysabri, Vumerity
Supernus Pharmaceuticals, INC. $589.49 2019-2024 Qelbree
Jazz Pharmaceuticals INC. $349.96 2023-2025
Harmony Biosciences LLC $316.25 2020-2024 Wakix
Celgene Corporation $289.02 2022-2025 Zeposia
Validus Pharmaceuticals LLC $258.67 2022-2025 Equetro
Eisai INC. $231.74 2020-2024
Ucb, INC. $194.47 2021-2022
Genentech USA, INC. $175.07 2019-2025 Ocrevus, Ocrevus Zunovo
Pfizer INC. $157.92 2019-2025
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Tanabe Pharma America, INC. $144.75 2022-2024
Sumitomo Pharma America, INC. $136.30 2023-2024 Aptiom
Lundbeck LLC $129.35 2019-2024 Rexulti
Emd Serono, INC. $115.00 2021-2022
Astrazeneca Pharmaceuticals LP $105.29 2022-2025 Wainua
Axsome Therapeutics, INC. $99.11 2023 Sunosi
Aprecia Pharmaceuticals, LLC $83.07 2020-2021
Hospira, INC. $82.46 2024
Catalyst Pharmaceuticals, INC. $78.24 2021-2024
Avadel Cns Pharmaceuticals, LLC $60.99 2023-2025 Lumryz
Aucta Pharmaceuticals, INC. $59.57 2024-2025 Motpoly Xr
Otsuka America Pharmaceutical, INC. $56.87 2024-2025 Rexulti
E.R. Squibb & Sons, L.L.C. $38.41 2020
Genzyme Corporation $36.07 2021
Sk Life Science, INC. $31.61 2020
Alexion Pharmaceuticals, INC. $31.07 2024 Ultomiris
Vertical Pharmaceuticals, LLC $29.71 2019
Avanir Pharmaceuticals, INC. $27.83 2020
Inspire Medical Systems, INC. $24.39 2023 Inspire
Acorda Therapeutics, INC $23.37 2019
Bausch Health US, LLC $22.96 2019
Banner Life Sciences, LLC $19.59 2022
Ani Pharmaceuticals, INC. $18.66 2024 Purified Cortrophin Gel
Mallinckrodt Hospital Products INC. $18.37 2020
Greenwich Biosciences, INC. $17.40 2021
Horizon Therapeutics Plc $16.96 2021
Merz North America, INC. $14.83 2019
Alfasigma USA, INC. $13.67 2021
Cycle Pharmaceuticals INC $12.81 2024 Tascenso Odt
Sunovion Pharmaceuticals INC. $12.30 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Narayan P Verma

$21,479.55

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $848 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

https://glasscript.com/doctor/49247/narayan-p-verma

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.